RQ Bio has clinched $115 million in a Series A raise to advance a preclinical pipeline of virus-targeting antibodies.
Four years after emerging from stealth with antibodies to prevent Covid-19 infections, RQ Bio has clinched $115 million in a Series A raise to advance …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
The startup claims to have a “differentiated” antibody that can provide long-lasting protection against a variety of influenza…
City Therapeutics raises $99.5M Series B to advance three RNAi candidates into the clinic and expand its delivery platform beyond…
MU Biosciences has extended its Series A to over $53 million in an oversubscribed round co-led by IQ Capital and Molten Ventures.
Full-Life Technologies gets $150M; Quince finds a new life; China biotech gets $50M; SERB Pharmaceuticals buys rights to Hansa…
Latus Bio raised $42 million as it prepares to seek FDA approval to start a clinical trial for its gene therapy for Huntington's…
If Parabilis follows through with its plans, that would make it one of the largest biotech IPOs of the past few years and the…
